Literature DB >> 21323498

Primary aldosteronism among newly diagnosed and untreated hypertensive patients in a Swedish primary care area.

Christina Westerdahl1, Anders Bergenfelz, Anders Isaksson, Christina Nerbrand, Stig Valdemarsson.   

Abstract

OBJECTIVE: To evaluate the prevalence of primary aldosteronism (PA) in newly diagnosed and untreated hypertensive patients in primary care using the aldosterone/renin ratio (ARR), and to assess clinical and biochemical characteristics in patients with high and normal ARR.
DESIGN: Patient survey study. SETTING AND
SUBJECTS: A total of 200 consecutive patients with newly diagnosed and untreated hypertension from six primary health care centres in Sweden were included. MAIN OUTCOME MEASURES: ARR was calculated from serum aldosterone and plasma renin concentrations. The cut-off level for ARR was 65. Patients with an increased ARR were considered for confirmatory testing with the fludrocortisone suppression test (FST), followed by adrenal computed tomographic radiology (CT) and adrenal venous sampling (AVS).
RESULTS: Of 200 patients, 36 patients had an ARR > 65. Of these 36 patients, 11 patients had an incomplete aldosterone inhibition during FST. Three patients were diagnosed with an aldosterone producing adenoma (APA) and eight with bilateral adrenal hyperplasia (BHA). Except for moderately lower level of P-K in patients with an ARR > 65 and in patients with PA, there were no biochemical or clinical differences found among hypertensive patients with PA compared with patients without PA.
CONCLUSION: Eleven of 200 evaluated patients (5.5%) were considered to have PA. The diagnosis of PA should therefore be considered in newly diagnosed hypertensive subjects and screening for the diagnosis is warranted.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21323498      PMCID: PMC3347934          DOI: 10.3109/02813432.2011.554015

Source DB:  PubMed          Journal:  Scand J Prim Health Care        ISSN: 0281-3432            Impact factor:   2.581


  30 in total

1.  Potentially high prevalence of primary aldosteronism in a primary-care population.

Authors:  P O Lim; P Rodgers; K Cardale; A D Watson; T M MacDonald
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

2.  Primary aldosteronism.

Authors:  J W CONN
Journal:  J Lab Clin Med       Date:  1955-04

Review 3.  Diagnosis of primary aldosteronism: from screening to subtype differentiation.

Authors:  Paolo Mulatero; Robert G Dluhy; Gilberta Giacchetti; Marco Boscaro; Franco Veglio; Paul M Stewart
Journal:  Trends Endocrinol Metab       Date:  2005-04       Impact factor: 12.015

4.  Screening for primary aldosteronism with a logistic multivariate discriminant analysis.

Authors:  G P Rossi; E Rossi; E Pavan; N Rosati; R Zecchel; A Semplicini; F Perazzoli; A C Pessina
Journal:  Clin Endocrinol (Oxf)       Date:  1998-12       Impact factor: 3.478

Review 5.  Cost-benefit of treating hypertension.

Authors:  B G Jönsson
Journal:  J Hypertens Suppl       Date:  1994-12

6.  Hyperaldosteronism: sampling the adrenal veins.

Authors:  J L Doppman; J R Gill
Journal:  Radiology       Date:  1996-02       Impact factor: 11.105

Review 7.  Primary aldosteronism: A common and curable form of hypertension.

Authors:  W F Young
Journal:  Cardiol Rev       Date:  1999 Jul-Aug       Impact factor: 2.644

8.  The cost-effectiveness of hypertension treatment in Sweden: an analysis of the criteria for intervention and the choice of drug treatment.

Authors:  M Johannesson
Journal:  J Hum Hypertens       Date:  1996-02       Impact factor: 3.012

9.  Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

Authors:  Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

10.  Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication.

Authors:  Lysann Seiler; Lars C Rump; Jürgen Schulte-Mönting; Marc Slawik; Katrin Borm; Hermann Pavenstädt; Felix Beuschlein; Martin Reincke
Journal:  Eur J Endocrinol       Date:  2004-03       Impact factor: 6.664

View more
  11 in total

Review 1.  Primary aldosteronism: a common cause of resistant hypertension.

Authors:  Gregory A Kline; Ally P H Prebtani; Alexander A Leung; Ernesto L Schiffrin
Journal:  CMAJ       Date:  2017-06-05       Impact factor: 8.262

Review 2.  Secondary Hypertension in Pregnancy.

Authors:  Line Malha; Phyllis August
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

3.  A subtype prediction score for primary aldosteronism.

Authors:  K Nanba; M Tsuiki; K Nakao; A Nanba; T Usui; T Tagami; Y Hirokawa; H Okuno; T Suzuki; T Shimbo; A Shimatsu; M Naruse
Journal:  J Hum Hypertens       Date:  2014-04-03       Impact factor: 3.012

4.  Misdiagnosis of a hidden cause of hypertension: a case report.

Authors:  Andrés de Lima; Farah El-Sharkawy; Carol Nieroda; Armando Sardi
Journal:  Br J Gen Pract       Date:  2017-12       Impact factor: 5.386

Review 5.  Primary aldosteronism is a public health issue: challenges and opportunities.

Authors:  Renata Libianto; Peter J Fuller; Morag J Young; Jun Yang
Journal:  J Hum Hypertens       Date:  2020-04-27       Impact factor: 3.012

6.  The evaluation and treatment of endocrine forms of hypertension.

Authors:  Alejandro Velasco; Wanpen Vongpatanasin
Journal:  Curr Cardiol Rep       Date:  2014-09       Impact factor: 2.931

7.  Prevalence of primary aldosteronism in primary care: a cross-sectional study.

Authors:  Sabine C Käyser; Jaap Deinum; Wim Jc de Grauw; Bianca Wm Schalk; Hans Jhj Bor; Jacques Wm Lenders; Tjard R Schermer; Marion Cj Biermans
Journal:  Br J Gen Pract       Date:  2018-01-15       Impact factor: 5.386

Review 8.  Primary aldosteronism.

Authors:  Sean M Wrenn; Anand Vaidya; Carrie C Lubitz
Journal:  Gland Surg       Date:  2020-02

9.  Catheterization during adrenal vein sampling for primary aldosteronism: failure to use (1-24) ACTH may increase apparent failure rate.

Authors:  Gregory A Kline; Benny So; Valerian C Dias; Adrian Harvey; Janice L Pasieka
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-11       Impact factor: 3.738

10.  Cost-Effectiveness of Therapeutic Drug Monitoring in Diagnosing Primary Aldosteronism in Patients With Resistant Hypertension.

Authors:  Alejandro Velasco; Oliver Chung; Fayez Raza; Ambarish Pandey; Stephanie Brinker; Debbie Arbique; Angela Price; Yair Lotan; Sandeep R Das; Wanpen Vongpatanasin
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-04-27       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.